Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) for the… read more.
A combination of hormone therapy and pelvic lymph node radiation improves survival of prostate cancer patients, researchers reported on May 26, 2022 in The Lancet. “We can now… read more.
Percutaneous nephrolithotomy (PCNL) is an efficient, minimally-invasive, gold standard procedure used for removing large kidney stones. Creating an access from the skin on the back to the kidney… read more.
Researchers from Sweden have reported that, compared with men with no prostate cancer, men diagnosed with prostate cancer have a significantly higher risk of developing venous thromboembolism (VTE)… read more.
Robot-assisted surgery used to perform bladder cancer removal and reconstruction enables patients to recover far more quickly and spend significantly (20 per cent) less time in hospital, concludes… read more.
Adding an anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumor growth, according to a proof-of-concept study led by Cedars-Sinai Cancerinvestigators. The… read more.
Hansa Biopharma AB, the pioneer in enzyme technology for rare immunological conditions, announced that its first-in-class treatment Idefirix (imlifidase) has been granted early access post marketing authorization (Autorisation… read more.
Depression and other mental health outcomes are similar for men choosing different options for initial treatment of localized prostate cancer, reports a study in The Journal of Urology®, an… read more.
In a retrospective study of adults initiating kidney failure treatment during 2011-2018, disparities in kidney transplantation by race were highest among patients age 22-44 years of age. Within this… read more.
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus… read more.
Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men… read more.
New study finds women who experience recurrent UTIs are unhappy with limited management options for the painful condition. Despite the prevalence of the painful condition, women are fearful and… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
